Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled trial of vasopressin injection for distributive shock with persistent hypotension
CTR20221292Phase 3Completed
- Sponsor
- Gowell
- Start
- Mar 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Vasoplegia comparing Vasopressin injection with Placebo saline control (2 arms). Primary endpoint: MAP response rate at 3 hours. Started Mar 2023; status: completed.
02
Drugs
vasopressin
03
Conditions
Vasoplegia
Beyond the preview
Go deeper on CTR20221292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221292.